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ABSTRACT
Objective: Patients who survive from the first stroke have risk factors to be recurrent. Based on American Heart Association/American Stroke 
Association and PERDOSSI (Indonesian Neurologist Association), medications which are prescribed to reduce the risk of recurrent stroke as 
secondary stroke prevention therapies include antiplatelet/anticoagulant as well as antihypertensive and lipid-lowering agent. Patients’ adherence to 
the secondary stroke prevention therapies is important to reduce the recurrent stroke.
Methods: This is a quantitative research and the data were collected retrospectively. The number of subjects of this study was 165 respondents. 
The participants were interviewed by researchers about their adherence to secondary stroke prevention by modified Morisky Adherence scale 8 
(MMAS-8) questionnaire. Patients’ adherence was stated as low (MMAS-8 score <6), moderate (MMAS-8 score =6-7), and high (MMAS-8 =8). This 
research was taken at a teaching hospital in Central Java Indonesia.
Results: Of 165 participants, 48 participants (29%) were categorized to have low adherence, 43 participants (26%) had moderate adherence, and 
74 participants (45%) had high adherence to secondary stroke prevention therapies. The reasons for not adhering to the medications were felt better 
(34.1%), forgetfulness (18.7%), boredom (16.5%), lack of family support (8.8%), lack of time (6.6%), felt worse (5.5%), concern about side effects 
(3.3%), preference to complementary alternative medicines (3.3%), and cost (3.3%).
Conclusion: The number of patients who has high adherence to secondary stroke prevention was 45% and the most common reason why participants 
did not adhere to therapy was because they felt better (34.1%).
Keywords: Recurrent stroke, Secondary prevention therapy, Adherence.
INTRODUCTION
Stroke is the second leading of death in the world. In the US, stroke 
is the third most common of mortality after cardiovascular disease 
and cancer [1]. Whereas in Indonesia, based on the data basis health 
research [2], number of patients who have diagnosed stroke are 
2,137,941 patients (12.1%). Patients who survive from the first stroke 
have risk factor to be recurrent. 1 of 6 patients who recover from the 
first stroke will experience recurrent stroke and 25% of them were fatal 
within 28 days [3]. In Mayapada hospital, there were 52.8% patients 
who have recurrent stroke [4].
According to American Heart Association/American Stroke Association 
and PERDOSI (Indonesian Neurologist Association), recurrent stroke 
would be minimized using secondary stroke prevention therapy 
including antiplatelet therapy/anticoagulants, antihypertensive, and 
lipid-lowering agent [5-8]. Optimal secondary prevention therapy can 
prevent recurrent stroke by 80% [9].
Prescription of secondary stroke prevention therapy is only the 
first step. If patients are not willing or able to take that medications, 
then the prescription was meaningless [10]. The medication 
of secondary prevention therapy of stroke and adherence is 
important to reach goal therapy and it can reduce the recurrent 
stroke [11].
This research objective was to describe of adherence survivor from the 
first stroke to use secondary prevention as well as to reveal reason not 
to be adhere to the therapy.
METHODS
Research design
This is a qualitative research and the data were collected retrospectively. 
This study was conducted between October and November 2014. 
Population in this research was patients who have experience and 
survive for the first stroke. The primary data were an interview from 
the patients and the secondary data came from medical records. 
Medical record data were selected based on the diagnosed physician 
about the stroke. Sampling was conducted by consecutive sampling 
which participants met the inclusions and exclusion criteria. Inclusion 
criteria were patients who diagnosed stroke and the information of 
medical record was complete. The exclusion criteria were patients who 
have experience for hemorrhagic or transient ischemic attack.
Procedure of research
Approval of the study was obtained from health Research Ethics 
Committee of Dr. Moewardi General Hospital/School of Medicine Sebelas 
Maret University number 551/X/HREC/2014 before the commencement 
of the study. Informed concerned was done and participants’ 
confidentiality was maintained during and after collecting data.
During the research period, 165 participants met the inclusion and 
exclusion criteria. After completing inform sheet that prepared before 
from the medical records about the characteristic of respondents or 
respondents’ demographic, history of illness, social history, history of 
using secondary prevention including antiplatelet/anticoagulant as 
well as antihypertensive and lipid-lowering agent; then, the participants 
were interviewed by researcher about adherence of taking secondary 
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stroke prevention therapies with modified Morisky adherence scale 
(MMAS-8) questionnaire and also participants have been given the 
open-ended question regarding the reason why participants not to be 
adhere to the therapy.
The scores of MMAS-8 questionnaire range from 0 to 8. There are three 
categories of adherent patients: high adherence patients with a score 
of 8 on the scale, moderate adherers with a score of 6 to < 8, and low 
adherers with a score of <6.
RESULTS
Before MMAS-8 was used, it has been validated and this questionnaire 
was valid and reliable to use as a tool to know the adherence of patients.
Of the 179 patients enrolled, 14 patients were excluded because 
10 patients diagnosed hemorrhagic and the data of 2 patients were not 
complete. A total of 165 patients were included in this analysis which 
consists of 84 men (51%) and 81 women (49%). Table 1 shows the 
baseline characteristic of the analysis. The mean age was 59.56 (range 
37-85) and Table 2 shows the medical history of patients.
From the Table 2, it revealed that most people has hypertension 
disease. It was about 82%. 50% of participants have experience of 
recurrent stroke, 27% of participants have diabetes mellitus, and 25% 
have hypercholesterolemia.
Tables 3 and 4 show the stage of adherence and the reason why 
patients do not adhere to the secondary prevention therapies. Of 
165 participants, 48 participants (29%) were categorized to have 
low adherence, 43 participants (26%) had moderate adherence, 
and 74 participants (45%) had high adherence to secondary stroke 
prevention therapies. The reasons for not adhering to the medications 
were felt better (34.1%), forgetfulness (18.7%), boredom (16.5%), lack 
of family support (8.8%), lack of time (6.6%), felt worse (5.5%), concern 
about side effect (3.3%), preference to complementary alternative 
medicines (3.3%), and cost (3.3%).
DISCUSSION
This study described the adherent to secondary stroke prevention 
therapies of survivor patients from the first stroke and to reveal the 
reason not to adhere to the therapy.
The study found that patient’s compliance in high stage was 45%. When 
compared with the prior investigations by 6 months, therapy had been 
discontinued in 8% (aspirin), 20% (angiotensin-converting enzyme 
inhibitors), and 13% (statin) [12]. Based on Bengaluru et al., research 
in 2014, of 858,835 survivors from the first stroke, shows that their 
adherence to take secondary prevention therapy of stroke was low [13]. 
For the first prescription, all of patients or 100% of patients took the 
medication, but for the next prescription, only around 88% took the 
medicines and the next, only approximately 47% patient continued to 
take their medication. A study in United States reported that 22% of 
patients take less of their medication than is prescribed [14].
Among the participants, more than half of participants were male. It 
was about 51%. This study is in accordance with another study showed 
that of 543 recruited patients, 51% were males with a mean age of 
74.7 years (range 22-29) [15].
82% of survivors have experience of hypertension. High blood pressure 
is a major risk factor for stroke. Hypertension was the most frequent 
risk factor (63.3% in men and 70.1% in women), followed by diabetes 
and smoking [16]. Hypertension is one of the modifiable risk factors 
for stroke. The other risk factors are diabetes mellitus, heart disease, 
cigarette smoking, dyslipidemia, and alcohol abuse [17].
The heart and soul study shows that coronary artery disease patients 
who only takes 75% medicines or less has risk factor to be recurrent 
stroke four times than patients who is 100% adherence [18]. On 
the other hand, if patients adherence to take secondary prevention 
medications, recurrent stroke event can be reduced by 57% [18]. The 
impact of non-adherence related to the mortality, morbidity, the raising 
hospitalization, and unnecessary cost [19,20]. Around 125,000 deaths 
per year in the United States are linked to non-adherent to medication. 
Between 33% and 69% of hospital admission is regarding to the poor 
of adherence to their medication, with total cost estimates ranging 
from $100 to 300 billion each year including costs for additional doctor 
visits, emergency room visits, hospital admission, and additional 
medicines [19].
There are many barriers that influence of adherence. First, it is about 
prescriber-related barriers such as limited time with the patients, 
lack of incentive to spend additional time counseling on adherence, 
Table 1: Baseline characteristic patients
Demographics Minimum Maximum Mean±SD
Age, years 37 85 59.56±10.753
Clinical presentation
SBP (mmHg) 100 230 147.58±28.245
DBP (mmHg) 50 180 90.77±16.37
At time plasma glucose 33 513 161.59±79.459
Fasting plasma glucose 24 308 115.41±46.604
2 hrs postprandial 
plasma glucose
69 412 157.97±56.537
Total cholesterol (mg/dl) 83 385 191.57±48.153
HDL-cholesterol (mg/dl) 17 72 38.61±10.758
LDL-cholesterol (mg/dl) 36 270 124.67±42.236
Triglyceride (mg/dl) 38 410 138.54±70.027
SBP: Systolic blood pressure , DBP: Diastolic blood pressure, LDL: Low-density 
lipoprotein, HDL: High-density lipoproteins
Table 2: Medical history of patients
Medical history n (%)
Hypertension 135 (82)
Diabetes mellitus 45 (27)
Hypercholesterolemia 42 (25)
Recurrent stroke 82 (50)
Congestive heart failure 36 (22)
Smoking 24 (15)




Table 3: Stage of adherence




Table 4: Reason not to adhere
Reasons not to adhere n=91 (%)
Felt better 31 (34.1)
Forgetfulness 17 (18.7)
Boredom 15 (16.5)
Lack of family support 8 (8.8)
Lack of time 6 (6.6)
Felt worse 5 (5.5)
Concert about side effect 3 (3.3)
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and uncomfortable speaking to patients about adherence. Second, 
it is pharmacist-related barriers for instance limited time to review 
medication refill patient histories, face difficulty to communicate with 
prescribers, and has limited access on patient medical record especially 
ambulatory patients. The last barrier is patient-related barriers such as 
complexity of medication regimen, high cost, concern about side effects, 
or adverse effects, receives contradictory information from health-care 
providers, a lack of knowledge about the medications, forgetfulness, 
and the other unexplained factors [14].
The most common reasons given by patients for not taking their 
medication are because they felt better (34.1%). They think that their 
condition has been well, so they do not take the medicines. The other 
causes of not taking medicine are forgetfulness (18.7%), boredom 
(16.5%), lack of family support (8.8%), lack of time (6.6%), felt worse 
(5.5%), concern about side effect (3.3%), preference to complementary 
alternative medicines (3.3%), and cost (3.3%). The reasons could 
be divided two groups that are intentional non-adherence and 
unintentional non-adherence. Intentional non-adherence can be 
considered as active process which the patients not follow the treatment 
recommendations because of their belief, or lack of knowledge, or lack 
of motivation regarding the medication. For example, people become 
skeptical about their medication because of side effect and other 
disadvantages such as drug dependency and reduce long-term efficacy. 
Counseling and providing education may improve the adherence [21].
On the other hand, unintentional non-adherence refers to unplanned 
behavior or passive process that it is not related to the beliefs and 
level of cognition. Patients may be careless or forgetful about adhering 
to the treatment regimen that they should take. Intervention for this 
type of non-adherence may need to focus on reminding patients and 
supporting patient to take their medications in their daily routine [21].
Limitations of the study
We acknowledge that this study had limitation. It was based mainly on 
the information obtained from medical records and patient information. 
We did not assess the health-care system that may influence of 
adherence to the patient adherence.
CONCLUSION
The study revealed that patient’s compliance in high stage was 45%. 
Prescription of secondary stroke prevention is important, but adherent 
is as important as the prescription. Health-care staffs not only physician 
but also pharmacist could take the responsibility to improve patient’s 
adherence to achieve the goal outcome of therapy by giving more 
attention to the secondary prevention and providing stroke patients 
with detailed instructions for medication usage. The goal therapy 
using secondary stroke prevention is not only to reduce mortality and 
morbidity but also to improve patient’s quality of life and prevent the 
recurrent stroke as well. Pharmacist counseling may effect to improve 
the patients adherence.
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